RISK OF HEPATITIS B INFECTION REACTIVATION IN RHEUMATIC DISEASES PATIENTS TREATED WITH ANTI-CD20 THERAPY

被引：0
|
作者：
Fornaro, M. [1 ]
Lopalco, G. [1 ]
Venerito, V. [1 ]
Barone, M. [2 ]
Cantarini, L. [3 ]
Fabiani, C. [4 ]
Emmi, G. [5 ]
Silvestri, E. [5 ]
Lapadula, G. [1 ]
Lannone, F. [1 ]
机构：
[1] Univ Bari, Dept Emergency & Organs Transplantat DETO, Rheumatol Unit, Bari, Italy
[2] Univ Aldo Moro, Dept Emergency & Organ Transplantat, Sect Gastroenterol, Piazza Giulio Cesare, I-70124 Bari, Italy
[3] Univ Siena, Rheumatol Unit Policlin Scotte, Siena, Italy
[4] Humanitas Clin & Res Ctr, Dept Ophthalmol, Rozzano, Milan, Italy
[5] Univ Florence, Dept Expt & Clin Med, Florence, Italy
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.6987
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0075
引用
收藏
页码：583 / 583
页数：1
相关论文
共 50 条
  • [1] Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases
    Oksbjerg, N. R.
    Nielsen, S. D.
    Blinkenberg, M.
    Magyari, M.
    Sellebjerg, F.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 52
  • [2] Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations
    Koutsianas, Christos
    Thomas, Konstantinos
    Vassilopoulos, Dimitrios
    [J]. THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2020, 12
  • [3] Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention
    Masaru Kato
    Tatsuya Atsumi
    [J]. Rheumatology International, 2016, 36 : 635 - 641
  • [4] Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention
    Kato, Masaru
    Atsumi, Tatsuya
    [J]. RHEUMATOLOGY INTERNATIONAL, 2016, 36 (05) : 635 - 641
  • [5] Herpes zoster infection in a cohort of RA patients treated with in anti-CD20
    Atzeni, F.
    Antivalle, M.
    Bertani, L.
    Batticciotto, A.
    Ventura, D.
    Mutti, A.
    Boccassini, L.
    Sarzi-Puttini, P.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (01) : S89 - S90
  • [6] Preventing Hepatitis B Reactivation During Anti-CD20 Antibody Treatment in the Veterans Health Administration
    Bullard, A. Jasmine
    Cunningham, Francesca E.
    Volpp, Bryan D.
    Lowy, Elliott
    Beste, Lauren A.
    Heron, Bernadette B.
    Geraci, Mark
    Hammond, Julia M.
    LaPlant, Kourtney
    Stave, Elise A.
    Turner, Marshal
    O'Leary, Meghan C.
    Kelley, Michael J.
    Hunt, D. Christine M.
    [J]. HEPATOLOGY COMMUNICATIONS, 2018, 2 (09) : 1136 - 1146
  • [7] Anti-cd20 therapy interferes with the immune response to the hepatitis b virus vaccine in ms patients
    Otero-Romero, S.
    Cardenas-Robledo, S.
    Rodriguez, M.
    Uriona, S.
    Rando, A.
    Vidal-Jordana, A.
    Esperalba, J.
    Del Amo, E.
    Rodrigo-Pendas, J.
    Campins, M.
    Martinez, X.
    Tintore, M.
    Montalban, X.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 260 - 260
  • [8] Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection
    Sayar, Suleyman
    Kurbuz, Kemal
    Kahraman, Resul
    Ozturk, Oguzhan
    Caliskan, Zuhal
    Doganay, Hamdi Levent
    Ozdil, Kamil
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2020, 31 (07): : 522 - 528
  • [9] B Cell Targeting Therapy Using the Anti-CD20 Antibody in Autoimmune Diseases
    Tanaka, Yoshiya
    [J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2009, 129 (06): : 675 - 679
  • [10] BLOCKING B-CELLS (ANTI-CD20/ANTI-CD20)
    Isenberg, David A.
    [J]. RHEUMATOLOGY, 2015, 54 : 1 - 1
12345